Salvatore Privitera Acquires 5,000 Shares of AtriCure, Inc. (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRCGet Free Report) insider Salvatore Privitera acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was bought at an average price of $22.25 per share, with a total value of $111,250.00. Following the transaction, the insider now directly owns 103,290 shares in the company, valued at $2,298,202.50. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

AtriCure Stock Up 1.3 %

Shares of NASDAQ:ATRC opened at $22.54 on Friday. The company has a 50 day moving average price of $24.11 and a two-hundred day moving average price of $31.23. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 4.00. The company has a market capitalization of $1.07 billion, a PE ratio of -28.18 and a beta of 1.41. AtriCure, Inc. has a 52 week low of $20.19 and a 52 week high of $59.61.

AtriCure (NASDAQ:ATRCGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The firm had revenue of $108.90 million during the quarter, compared to the consensus estimate of $106.86 million. AtriCure had a negative net margin of 8.98% and a negative return on equity of 7.85%. AtriCure’s quarterly revenue was up 16.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.23) EPS. Analysts forecast that AtriCure, Inc. will post -0.75 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Oppenheimer upgraded AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 target price for the company in a research report on Tuesday, April 23rd. Stifel Nicolaus cut their target price on shares of AtriCure from $50.00 to $42.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Canaccord Genuity Group lowered their price target on shares of AtriCure from $57.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. UBS Group increased their price objective on shares of AtriCure from $57.00 to $58.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, StockNews.com cut shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, AtriCure currently has a consensus rating of “Moderate Buy” and an average target price of $49.78.

View Our Latest Analysis on AtriCure

Hedge Funds Weigh In On AtriCure

Several institutional investors have recently modified their holdings of the business. State of New Jersey Common Pension Fund D lifted its stake in AtriCure by 31.1% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 68,188 shares of the medical device company’s stock valued at $2,434,000 after buying an additional 16,168 shares in the last quarter. Knights of Columbus Asset Advisors LLC increased its position in shares of AtriCure by 165.8% during the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 123,540 shares of the medical device company’s stock worth $4,409,000 after acquiring an additional 77,055 shares in the last quarter. Bridger Management LLC acquired a new stake in shares of AtriCure during the fourth quarter worth $3,109,000. Panagora Asset Management Inc. lifted its position in AtriCure by 38.0% in the 4th quarter. Panagora Asset Management Inc. now owns 229,197 shares of the medical device company’s stock valued at $8,180,000 after acquiring an additional 63,079 shares in the last quarter. Finally, CenterBook Partners LP acquired a new position in AtriCure in the 3rd quarter worth $770,000. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

Featured Stories

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.